| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
CVT-6883 manufacturers
- GS-6201
-
- $68.00
-
2026-09-10
- CAS:752222-83-6
- Purity: 99.94%
- Supply Ability: 10g
- CVT 6883
-
- $1.00
-
2020-01-13
- CAS:752222-83-6
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 1ton
|
| | CVT-6883 Basic information |
| Product Name: | CVT-6883 | | Synonyms: | CVT-6883;3-Ethyl-1-propyl-8-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-3,7-dihydro-purine-2,6-dione;GS6201 CVT6883;GS-6201;3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoroMethyl)phenyl]Methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione;3-Ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,8H)-dione;GS 6201; GS6201; GS6201; CVT6883; CVT-6883;1H-Purine-2,6-dione, 3-ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]- | | CAS: | 752222-83-6 | | MF: | C21H21F3N6O2 | | MW: | 446.43 | | EINECS: | 200-258-5 | | Product Categories: | | | Mol File: | 752222-83-6.mol |  |
| | CVT-6883 Chemical Properties |
| Boiling point | 639.6±65.0 °C(Predicted) | | density | 1.44 | | storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 7.69±0.70(Predicted) | | color | White to light brown |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | CVT-6883 Usage And Synthesis |
| Uses | 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione, is a novel selective, high-affinity A2B adenosine receptor (AR) antagonist, used for the treatment of inflammatory and angiogenic diseases. | | Biological Activity | GS-6201 (CVT-6883) is a potent and selective A2B adenosine receptor (A2BAdoR) antagonist. GS-6201 reduces caspase-1 activity in the heart and leads to a more favorable cardiac remodeling in a mouse model of non-reperfused myocardial infarction. Also GS-6201 attenuated vascular remodeling and hypertension in mouse model. | | in vivo | GS-6201 (CVT-6883) (4 mg/kg; i.p.; every 12 h for 14 days) significantly reduces IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels[2].
GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) leads to a significant attenuation of left and right ventricular enlargement and dysfunction at 7 days, which was maintained at 14 days and also at 28 days[2].
GS-6201 (2 mg/kg; p.o.) treatment shows the Cmax, dAUC and t1/2 are 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively[1]. | Animal Model: | Adult out-bred male CD1 mice (8-12 weeks of age, AMI model)[2] | | Dosage: | 4 mg/kg | | Administration: | i.p.; every 12 h for 14 days | | Result: | Significantly reduced IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels. |
| Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 2 mg/kg | | Administration: | p.o. (Pharmacokinetic Analysis) | | Result: | The Cmax, dAUC and t1/2 were 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively. |
| | storage | Store at -20°C |
| | CVT-6883 Preparation Products And Raw materials |
|